
## **Camila R Fontes-Garfias**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9595630/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity. Cell Reports, 2022, 39, 110655.	2.9	20
2	Evaluation of a SARS-CoV-2 lateral flow assay using the plaque reduction neutralization test. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115248.	0.8	13
3	Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 2021, 592, 116-121.	13.7	1,380
4	A genetically stable Zika virus vaccine candidate protects mice against virus infection and vertical transmission. Npj Vaccines, 2021, 6, 27.	2.9	5
5	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 2021, 592, 283-289.	13.7	494
6	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Medicine, 2021, 27, 620-621.	15.2	562
7	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. Npj Vaccines, 2021, 6, 44.	2.9	36
8	Neutralizing Activity of BNT162b2-Elicited Serum. New England Journal of Medicine, 2021, 384, 1466-1468.	13.9	528
9	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature, 2021, 595, 572-577.	13.7	583
10	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. New England Journal of Medicine, 2021, 385, 472-474.	13.9	93
11	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI Insight, 2021, 6, .	2.3	46
12	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nature Communications, 2020, 11, 5214.	5.8	179
13	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 2020, 586, 594-599.	13.7	1,520
14	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	13.9	2,107
15	PhaseÂl/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 2020, 586, 589-593.	13.7	1,197
16	A Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and fitness for transmission. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20190-20197.	3.3	53
17	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nature Communications, 2020, 11, 4059.	5.8	266
18	Reverse genetic approaches for the development of Zika vaccines and therapeutics. Current Opinion in Virology, 2020, 44, 7-15.	2.6	3

#	Article	IF	CITATIONS
19	Genetic stability of live-attenuated Zika vaccine candidates. Antiviral Research, 2019, 171, 104596.	1.9	6
20	An attenuated Zika virus NS4B protein mutant is a potent inducer of antiviral immune responses. Npj Vaccines, 2019, 4, 48.	2.9	14
21	3′ UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk. Nature Genetics, 2018, 50, 783-789.	9.4	148
22	Functional Analysis of Glycosylation of Zika Virus Envelope Protein. Cell Reports, 2017, 21, 1180-1190.	2.9	118